首页> 外文OA文献 >Proteínas SAG1, SAG2, SAG3 de toxoplasma gondii como perspectivas para o desenvolvimento de protótipo vacinal contra a toxoplasmose
【2h】

Proteínas SAG1, SAG2, SAG3 de toxoplasma gondii como perspectivas para o desenvolvimento de protótipo vacinal contra a toxoplasmose

机译:弓形虫的SAG1,SAG2,SAG3蛋白作为开发抗弓形虫疫苗原型的前景

摘要

Toxoplasmosis is a zoonosis of worldwide distribution caused by the protozoan Toxoplasma gondii, triggering dangerous complications in immunocompromised patients and pregnant women, as well as having great economic impact for the livestock. So far the control of toxoplasmosis is made primarily by chemotherapy. However, most drugs used routinely have some limitations. In order to control this disease, several research groups, including ours, has been working to develop a medical-veterinary vaccine based on parasite antigens, vectors and protocols of immunization. In this study were implemented and standardized methodologies for amplification and cloning of recombinant immunogens in the system for the development of a prototype vaccine, based on the surface antigens of T. gondii and recombinant adenovirus encoding these antigens. Genes encoding BAG1, GRA2 and SAG1 proteins were amplified. We established a strategy for cloning SAG1, SAG2, SAG3 and TgAMA1- genes in recombinant system. The genes encoding SAG1 and SAG2 were cloned and their sequences showed high similarity with sequences from GenBank. The virtual translation of these proteins showed polymorphisms in the amino acid sequence, which can be correlated with levels of antigenicity. Simultaneously, the adenovirus encoding the SAGs (HAdSAGs) were expanded, purificated and characterizated. Immunization of C57bl/6 mice, using viral supernatant was not enought to elicit immune responses at high levels, being required HAdSAGs titration for future immunizations. Therefore, this study allowed the cloning of the two genes important for the development of a prototype vaccine. Besides, implementations methodologies that permit advancements in the development of a vaccine against toxoplasmosis using adenovirus to express proteins of the parasite
机译:弓形虫病是一种由弓形虫弓形虫引起的在世界范围内的人畜共患病,在免疫功能低下的患者和孕妇中引发危险的并发症,并对牲畜产生巨大的经济影响。到目前为止,弓形虫病的控制主要是通过化学疗法进行的。但是,大多数常规使用的药物都有一定的局限性。为了控制这种疾病,包括我们在内的几个研究小组一直在努力开发基于寄生虫抗原,载体和免疫方案的医学兽医疫苗。在这项研究中,基于刚地弓形虫的表面抗原和编码这些抗原的重组腺病毒,实施了标准化方法,用于在开发原型疫苗的系统中扩增和克隆重组免疫原。扩增了编码BAG1,GRA2和SAG1蛋白的基因。我们建立了在重组系统中克隆SAG1,SAG2,SAG3和TgAMA1-基因的策略。克隆了编码SAG1和SAG2的基因,其序列与GenBank的序列显示出高度相似性。这些蛋白质的虚拟翻译显示氨基酸序列中的多态性,这可以与抗原性水平相关。同时,扩增,纯化和表征了编码SAG的腺病毒(HAdSAG)。使用病毒上清液对C57bl / 6小鼠的免疫还不足以引发高水平的免疫反应,需要HAdSAG滴定才能用于未来的免疫。因此,该研究允许克隆对于开发原型疫苗重要的两个基因。此外,允许使用腺病毒表达抗寄生虫蛋白的弓形虫病疫苗开发取得进展的实施方法

著录项

  • 作者

    Moura Andrew Douglas;

  • 作者单位
  • 年度 2013
  • 总页数
  • 原文格式 PDF
  • 正文语种 por
  • 中图分类

相似文献

  • 外文文献
  • 中文文献
  • 专利

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号